A New N-terminal Recognition Domain in Caveolin-1 Interacts with Sterol Carrier Protein-2 (SCP-2)

Rebecca D. Parr  
*Stephen F Austin State University, parrrl@sfasu.edu*

Gregory G. Martin  
*Texas A & M University - College Station*

Heather A. Hostetler  
*Texas A & M University - College Station*

Megan E. Schroeder  
*Texas A & M University - College Station*

Kiran D. Mir  
*Texas A & M University - College Station*

See next page for additional authors

Follow this and additional works at: [https://scholarworks.sfasu.edu/biology](https://scholarworks.sfasu.edu/biology)
A New N-Terminal Recognition Domain in Caveolin-1 Interacts with Sterol Carrier Protein-2 (SCP-2)†

Rebecca D. Parr,‡ Gregory G. Martin,§ Heather A. Hostetter,§ Megan E. Schroeder,‡ Kiran D. Mir,¶ Ann B. Kier,‡ Judith M. Ball,*‡ and Friedhelm Schroeder§

Department of Pathobiology, Texas A&M University, TVMC, College Station, Texas 77843-4467, and Department of Physiology and Pharmacology, Texas A&M University, TVMC, College Station, Texas 77843-4466

Received February 7, 2007; Revised Manuscript Received April 27, 2007

ABSTRACT: Although plasma membrane domains, such as caveola, provide an organizing principle for signaling pathways and cholesterol homeostasis in the cell, relatively little is known regarding specific mechanisms, whereby intracellular lipid-binding proteins are targeted to caveola. Therefore, the interaction between caveolin-1 and sterol carrier protein-2 (SCP-2), a protein that binds and transfers both cholesterol and signaling lipids (e.g., phosphatidylinositol-4-phosphate and sphingolipids), was examined by yeast two-hybrid, in vitro binding and fluorescence resonance energy transfer (FRET) analyses. Results of the in vitro and in vitro assays identified for the first time the N-terminal amino acids (aa) 1–32 amphipathic α-helix of SCP-2 functionally interacted with caveolin-1. This interaction was independent of the classic caveolin-1 scaffolding domain, in which many signaling proteins interact. Instead, SCP-2 bound caveolin-1 through a new domain identified in the N-terminal domain of caveolin-1 between aa 34–40. Modeling studies suggested that electrostatic interactions between the SCP-2 N-terminal aa 1–32 amphipathic α-helical domain (cationic, positively charged face) and the caveolin-1 N-terminal aa 33–59 α helix (anionic, negatively charged face) may significantly contribute to this interaction. These findings provide new insights on how SCP-2 enhances cholesterol retention within the cell as well as regulates the distribution of signaling lipids, such as phosphoinositides and sphingolipids, at plasma membrane caveola.

Increasing evidence indicates that cholesterol found at the cell-surface plasma membrane (PM) is not randomly distributed but instead organized into lipid rafts and/or caveola, a subfraction of lipid rafts that have proven to be a remarkably stable structural and functional entity (9, 10). Diverse processes, such as transmembrane signal transduction (e.g., eNOS, estrogen, and insulin), the action of microbial (viruses, bacteria, and protozoa), and microbial (viruses, bacteria, and protozoa) entry into cells, are mediated through PM lipid rafts/caveola (reviewed in refs 4, 11, and 12). Depletion of cholesterol from the PM lipid rafts/caveola disrupts these functions. Because of these

† Abbreviations: aa, amino acids, Cav1, full-length caveolin; caveolin-1–156, C-terminal deletion mutant of caveolin-1 missing most of the C-terminal cytoplasmic domain; Cav 60–178, N-terminal deletion mutant of caveolin-1 missing almost all of the N-terminal cytoplasmic domain except for the signature domain; Cav A83–123, caveolin-1 deletion mutant missing part of the caveolin-1 scaffolding domain and part of the transmembrane domain; Cav A59–100, caveolin-1 deletion mutant missing all of the scaffolding and signature domains; SCP-2, sterol carrier protein-2; SR-B1, scavenger receptor B1; ABC-A1, ATP-binding cassette protein A1; Pgp, P-glycoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CSD, caveolin-1 scaffolding domain; CBD, caveolin-1 binding domain; L-FABP, liver fatty acid binding protein; CSM, complete synthetic media; CPRG, chlorophenol red β-D-galactopyranoside assay; SFOA, 5-fluoroacetic acid; Ura, uracil; PI, phosphoinositide; PtdIns, phosphatidylinositol; PtdIns-4-P, phosphatidylinositol-4-phosphate; PtdIns-4,5-P2, phosphatidylinositol-4,5-bisphosphate; M, molecular weight.
cells (e.g., hepatocytes) (14–17). Once bound to SRB1, HDL cholesteryl ester is transferred to the PM lipid rafts/caveolae, internalized by an unresolved, nonendocytic process, and undergoes hydrolysis by nonlysosomal, neutral esterases to free cholesterol (17, 18). Third, unidirectional cholesterol efflux occurs via the ATP-binding cassette transporter A1 (ABCA1) (19–21), which localizes to lipid rafts/caveolae (22, 23). ABCA1 binds apoprotein-1 (apoA1) to enhance phospholipid efflux, followed by ABCA1-independent cholesteryl transfer to the phospholipid containing apoA1, which then becomes HDL (21, 24). Fourth, the bidirectional cholesterol uptake/efflux pathway in which HDL binds to SRB1 is localized in lipid rafts/caveolae rafts and donates/takes up cholesterol by a process that is as yet unclear (15, 16, 21).

Although caveolin-1 expression is associated with increased cholesterol transport to caveolae and increased cholesterol efflux to HDL (14, 17, 25), SRB1 localization in caveolae is not required for cholesterol uptake/efflux (15). While there is considerable evidence that the multidrug resistance transporter P-glycoprotein (P-gp) also participates in SRB1-mediated cholesteryl transfer to/from bound HDL, it remains unclear whether P-gp resides in caveolae (26), in noncaveolar lipid rafts (27), or in an intermediate density membrane microdomain distinct from caveolae and classical lipid rafts (28). Many of these proteins appear to indirectly regulate/alter cholesterol flux between the PM and HDL by acting as phospholipid flippases (e.g., ABCA1, P-gp) (21, 24, 28, 29). Photo-cross-linking and immunoprecipitation studies show that (i) caveolin-1 (30, 31) but not ABCA1 (24) or SRB1 (14) directly binds cholesterol, (ii) ABCA1 and SRB1 but not caveolin-1 directly bind HDL (21, 22), (iii) while neither ABCA1, P-gp, or SRB1 contain a caveolin-1 “scaffold binding domain”, ABCA1 may interact directly with caveolin-1 (22). Thus, when caveolin-1 is directly bound, the ABCA1 may provide a scaffolding platform for cholesterol efflux through either the SRB1 or ABCA1 pathways.

Both vesicular and protein-mediated pathways appear to contribute to intracellular trafficking of cholesterol to and from lipid rafts/caveolae (4, 17, 32–34). At least three cholesterol binding proteins may be involved in protein-mediated cholesterol trafficking through the cytoplasm: caveolin-1, sterol carrier protein-2 (SCP-2), and liver fatty acid binding protein (L-FABP) (4, 35, 36). Bidirectional flux of free cholesterol and unidirectional uptake of cholesterol ester is thought to be mediated by cytoplasmic transport complexes of caveolin-1, cholesterol (or cholesterol ester), and one or more chaperone proteins (cytoplphilin A, cyclophilin 40, heat-shock protein 56, and/or annexin II). The mechanism(s) whereby these complexes dock/interact with PM caveolae appears to involve the CD44 receptor and cytoskeletal proteins (17). In contrast to caveolin-1, the other cholesterol binding proteins (L-FABP and SCP-2) have been reported to form simple molecular complexes with cholesterol (but not cholesteryl ester) to (i) enhance cholesterol uptake (SCP-2 \(\Rightarrow\) L-FABP), (ii) transfer cholesterol between membranes with which they interact (SCP-2 \(\Rightarrow\) L-FABP), and (iii) transfer cholesterol into bile (L-FABP) (35, 37–43). Notably, SCP-2 expression not only enhances cholesterol uptake (44) but also stimulates intracellular cholesterol esterification (45, 46) while concomitantly inhibiting cholesterol efflux to HDL (33). These findings suggest that caveolin-1 and SCP-2 may have antagonistic effects depending upon the cell context. As of yet, relatively little is known about the mechanism(s) whereby caveolin-1/cholesterol/chaperone, L-FABP cholesterol, and SCP-2 cholesterol complexes dock/interact with PM lipid rafts/caveolae.

Caveolin-1-interacting proteins have been shown to bind the caveolin-1 scaffolding domain (CSD) that resides in amino acids (aa) 80–101 of the central region of caveolin-1 (47). The caveolin-1 binding domain (CBD) is comprised of the recognition sequence \(\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Phi\Philosophy and ethics. The use of experimental animals is consistent with the guidelines for the use of animals in research established by the National Institutes of Health. All procedures were approved by the Animal Care and Use Committee of the National Institutes of Health. The study was conducted in compliance with the principles of laboratory animal care, and the guidelines for the use of experimental animals were followed.

**Materials and methods**

**Materials.** CNBr-activated Sepharose 4B beads were obtained from Amersham Biosciences (Piscataway, NJ). SCP-2 and caveolin-1 peptide-specific antibodies were generated in rabbits in our laboratory as described (50–53). Rabbit anti-human caveolin-1 was purchased from Jackson Immunoresearch Labs, Inc. (West Grove, CA) or Transduction Labs (San Diego, CA). Bound antibodies were detected by horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD or Pierce, Rockford, IL). Total protein was quantitated using the BCA protein assay kit (Pierce). Dulbecco’s modified Eagle medium (DMEM) was from Gibco (Grand Island, NY). Fetal bovine serum (FBS), glutamine, penicillin-streptomycin (100 µg/mL), and nonessential amino acid (1X) were from Sigma (St. Louis, MO).

**Mammalian Cell Culture.** MDCK cells were obtained from ATCC (Rockville, MD) and maintained in DMEM supplemented with 10% FBS, glutamine (2 mM), penicillin-streptomycin (100 µg/mL), and nonessential amino acid (1X). Because of the high expression level of caveolin-1 in MDCK cells (53), MDCK lysates were prepared as a source of caveolin-1 antigen. Murine L cells (L arpt-k-) were cultivated as previously described (54).

**Yeast Strains for Two-Hybrid Assay.** Saccharomyces cerevisiae strain MaV203 (MATa, leu2–3,112, trp1–901, his3A200, ade2–101, gal4Δ, gal80Δ, SPAL10::URA3, GAL1::lacZ, HIS3un gal1::HIS3@LYS2, can1′, cyh2′) was used for all two-hybrid analyses (55). A collection of yeast strains that contain plasmid pairs expressing fusion proteins with a spectrum of interaction strengths [pPC97 (GAL4-DB, LEU2), pPC97-CYH25, and pPC86 (GAL4-AD, TRP1)] were used as controls (53, 56–59). The control plasmids...
pDBlu and pEXP-AD507 contain only the Gal4 DNA-binding domain (BD) and the Gal4 activating domain (AD), respectively.

The *S. cerevisiae* yeast strain InVS1c (MATa his3-Δ1, leu2, trpl−289, ura3−52; Invitrogen, Carlsbad, CA) was used to induce the production of full-length caveolin-1, mutant caveolin-1, and SCP-2 proteins.

**Construction of Plasmids.** SCP-2 and full-length caveolin-1 cDNA were cloned into the Invitrogen Gateway Destination vectors pDEST22 and pDEST32 (ProQuest Two-Hybrid System with Gateway Technology Manual, Invitrogen Life Technologies, Inc.) as previously described (53, 55). The deletion mutant clones of caveolin-1, caveolin-1Δ1−156, 60−178, Δ60−100, and Δ83−123, were constructed by site-directed mutagenesis using the primers described to the right of each construct and cloned into the DNA-binding domain plasmid, pENTR11 (Invitrogen), as described above. The entry level clones (pENTR11) used to create the Gateway System entry vector, pENTR11 (Invitrogen), were transformed into DH5α LR Clonase Enzyme Mix (Invitrogen). The resultant clones were enzyme-digested with Wizard Miniprep kit (Promega, Madison, WI), restriction-amplification, recombinant plasmids were extracted using the standard protocols in the (Figure 1).

The deletion mutant clones of caveolin-1, caveolin-1Δ1−156, 60−178, Δ60−100, and Δ83−123, were produced as described in the Materials and Methods.

The *S. cerevisiae* yeast strain InVS1 (MATa his3-Δ1, leu2, trpl−289, ura3−52; Invitrogen, Carlsbad, CA) was used to induce the production of full-length caveolin-1, mutant caveolin-1, and SCP-2 proteins.

**Construction of Plasmids.** SCP-2 and full-length caveolin-1 cDNA were cloned into the Invitrogen Gateway Destination vectors pDEST22 and pDEST32 (ProQuest Two-Hybrid System with Gateway Technology Manual, Invitrogen Life Technologies, Inc.) as previously described (53, 55). The deletion mutant clones of caveolin-1, caveolin-1Δ1−156, 60−178, Δ60−100, and Δ83−123, were constructed by site-directed mutagenesis using the primers described to the right of each construct and cloned into the DNA-binding domain plasmid, pENTR11 (Invitrogen), as described above. The entry level clones (pENTR11) used to create the Gateway System entry vector, pENTR11 (Invitrogen), were transformed into DH5α LR Clonase Enzyme Mix (Invitrogen). The resultant clones were enzyme-digested with Wizard Miniprep kit (Promega, Madison, WI), restriction-amplification, recombinant plasmids were extracted using the standard protocols in the (Figure 1).

The deletion mutant clones of caveolin-1, caveolin-1Δ1−156, 60−178, Δ60−100, and Δ83−123, were produced as described in the Materials and Methods.

The *S. cerevisiae* yeast strain InVS1 (MATa his3-Δ1, leu2, trpl−289, ura3−52; Invitrogen, Carlsbad, CA) was used to induce the production of full-length caveolin-1, mutant caveolin-1, and SCP-2 proteins.

**Expression of SCP-2, Caveolin-1, and Mutant Caveolin-1 in Yeast.** The entry level clones (pENTR11) used to create the yeast two-hybrid expression clones were also employed to introduce the sequences encoding SCP-2, caveolin-1, and mutant caveolin-1 proteins into the inducible yeast expression plasmid, pY52DEST (Invitrogen), as described above. Transformants were first grown on CSMU− plates, transferred to liquid CSMU−, and induced with galactose in YPAG [yeast extract, peptone, and 2% galactose (Difco)] medium to express full-length SCP-2 and caveolin-1 or the four deletion caveolin-1 mutants. Briefly, cells were grown in liquid CSMU− medium at 30 °C for 24 h, washed and resuspended at an OD600 of 0.5 in YPAG, and incubated at 30 °C for 24 h. Yeast protein cell lysates were prepared using the Zymo Yeast Protein Extraction kit (Zymo Research, Orange, CA) as previously described (50) and used in the binding and Western blot assays to detect SCP-2, caveolin-1, or mutant caveolin-1 proteins. Briefly, approximately 1 × 10^6 cells were pelleted; Y-lysis buffer and zymolase were added; and the samples were incubated at 37 °C for 1 h. The cells were centrifuged at 400 g for 5 min, and supernatants were removed. The pellets were resuspended in phosphate-buffered saline (PBS) with protease inhibitors (100 μM AEBSF, 80 nM Aprotinin, 5 μM Bestatin, 1.5 μM E-64, 2 μM Leupeptin, 1 μM Pepstatin A, and 100 μM PMSF, Calbiochem-Novabiochem Corp., San Diego, CA). The total protein in each pellet was quantitated using the BCA protein assay kit (Pierce). Approximately 10 μg of each pellet was separated on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), transferred to nitrocellulose, and probed with rabbit polyclonal SCP-2 or caveolin-1 antibodies (50, 53). The primary antibodies were detected using goat anti-rabbit-HRP antibodies (Pierce) followed by the addition of the Super Signal West Pico Chemiluminescent Substrate (Pierce), and bands were visualized using X-OMAT film (Kodak).

**Yeast Two-Hybrid Screening.** *S. cerevisiae* strain MaV203 (MATα, leu2−2,3,112, trpl−1,901, his3Δ200, ade2−101, gal4Δ, gal80Δ, SPAL10::URA3, GAL1::lacZ, HIS3::gal4::HIS3@LYS2, can1·, cyh2·) was used to test for protein–protein interactions of SCP-2 and either caveolin-1 or the mutants of caveolin-1 (58, 59). A panel of MaV103 (MATa) control strains containing the same genotype as MaV203 expressing a GAL4 DNA-binding fusion protein (DB−X) and a GAL4 transcription activating protein (AD−Y) with a spectrum of interaction strengths was replica-plated onto assay plates (49–52). The control vectors were pPC97 (GAL4-DB, LEU2), pPC97-CYH2, and pPC86 (GAL4-AD, TRP1). pDBlu and pEXP-AD507 contain only the Gal4

---

**Figure 1:** Linear schematic of full-length and deletion mutants of caveolin-1. The PCR fragments were produced using the forward and reverse primers listed to the right of each construct and cloned into the DNA-binding domain plasmid, pD22, and the activation-domain plasmid, pD32, of the ProQuest Yeast Two-Hybrid System with Gateway Technology. The full-length clone of caveolin-1 encodes 178 amino acids. One 3′ deletion mutant, Caveolin-1Δ1−156, one 5′ deletion mutant, CavΔ60−178, and two internal deletion mutants, CavΔ60−100 and Δ83−123, were produced as described in the Materials and Methods.

**Table 1:** Primers for site-directed mutagenesis.

<table>
<thead>
<tr>
<th>Primers</th>
<th>Mutation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5′-ATCGCTGGAGACGAAGCCGGAGA-3′</td>
<td>Δ289</td>
<td>Fused to the Gateway System entry vector, pENTR11 (Invitrogen), as described above. The entry level clones (pENTR11) used to create the Gateway System entry vector, pENTR11 (Invitrogen), were transformed into DH5α LR Clonase Enzyme Mix (Invitrogen). The resultant clones were enzyme-digested with Wizard Miniprep kit (Promega, Madison, WI), restriction-amplification, recombinant plasmids were extracted using the standard protocols in the (Figure 1).</td>
</tr>
</tbody>
</table>
DNA-binding domain (BD) and the Gal4 activating domain (AD), respectively. All plasmid manipulations were performed according to standard protocols for the E. coli strains DH5α (48, 53, 54). MaV203 yeast were transformed by a modified lithium acetate (LiAc) procedure as previously described (56–59). Briefly, S. cerevisiae MaV203 were grown in YPAD overnight at 30 °C, diluted to an OD600 of 0.5, and incubated at 30 °C with shaking to an OD600 of 2. The cells were pelleted, washed with distilled H2O, resuspended in 1 mL of 100 mM LiAc, pelleted, and resuspended in 0.4 mL of 100 mM LiAc, and 50 µL aliquots were pelleted. The following solutions were added in order: 240 µL of 50% PEG (M₅ = 3350), 36 µL of 1 M LiAc, 25 µL of salmon sperm DNA (2 mg/mL), 50 µL of H₂O, and 100 ng of each plasmid DNA.

Transformants were grown at 30 °C for 3 days on complete synthetic medium lacking leucine and tryptophan (CSMLeu-Trp) to identify colonies containing both plasmids. To determine the two-hybrid-dependent transcription activation by SCP-2 and caveolin-1 mutants of caveolin-1, the induction of the reporter genes, URA3 and HIS3, was evaluated by monitoring the yeast growth patterns on CSMLeu-Trp-Ura, CSMLeu-Trp + 0.2% 5FOA, and CSMLeu-Trp-His + 3AT (12.5, 50, and 100 mM 3AT) (50, 53). Activation of the LacZ promoter was detected qualitatively using the substrate X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). To quantitatively measure β-galactosidase activity, chlorophenol red-β-D-galactopyranoside (CPRG) was used as a substrate (50). To ensure that the DB-X or AD-Y fusion proteins do not function as transcription activators, yeast were transformed with the individual fusion constructs and evaluated for growth on all of the media described above.

Western Blot Assays. The colonies that appeared positive for protein–protein interactions as determined by the phenotypic growth patterns were grown in liquid CSMLeu-Trp, and yeast protein extracts were prepared using the Zymo Yeast Protein Extraction kit (Zymo Research, Orange, CA). In brief, cells were grown in YPAD medium overnight at 30 °C, and 1 × 10⁸ cells were pelleted, lysed with zymolase, resuspended in PBS at pH 7.2 containing protease inhibitors (above), and quantified by BCA (Pierce). All lysates were separated by 12% SDS–PAGE, electroblotted onto nitrocellulose membranes, and probed with SCP-2 or caveolin-1 peptide-specific antibodies and HRP-conjugated antibodies as previously described (50, 53, 55).

Protein Purification. The human recombinant mature 13 kDa SCP-2 and 15 kDa pro-SCP-2 were purified as described earlier (60). PEX 5C was generously provided by Dr. Jeremy Berg ( Johns Hopkins University).

In Vitro Caveolin-1 SCP-2 Binding Assay. To confirm the interactions of caveolin-1 and 13 kDa SCP-2 determined by the yeast two-hybrid assay, an in vitro binding assay was developed. Synthetic peptides corresponding to caveolin-1 residues 2–31, 19–40, 34–55, 76–101, and 161–178 (Table 1), a peptide corresponding to mature 13 kDa SCP-2 aa 1–32 (SCP-2₁₋₃₂), a peptide wherein residue aa20L was mutated to E (SCP-2₁₋₃₂E₂₀), and a peptide corresponding to the 20 aa presequence of pro-SCP-2 (SCP-2₁₋₂₀) present in 15 kDa pro-SCP-2 (61, 62) were synthesized as described earlier (Table 1) (63–65). SCP-2 residues 1–32 contain the N-terminal amphipathic α-helical region of mature 13 kDa SCP-2 and represent the membrane interaction domain of SCP-2 (63–65).

The peptides described above were attached to CNBr-activated Sepharose 4B beads as recommended by the manufacturer (Amersham Biosciences Corp., Piscataway, NJ). Aliquots (2 mg of total protein each) of InVSc-1 (does not express caveolin-1) or MDCK lysate (expresses caveolin-1) were incubated with 50 µL of a 50% slurry Sepharose 4B or Sepharose 4B-SCP-2₁₋₃₂ overnight at 4 °C with gentle mixing. The beads were pelleted by centrifugation, washed 3 times with wash buffer (10 mM Tris at pH 7.5 and 0.5 M NaCl), and resuspended in PBS containing protease inhibitors (above). Half of each sample was separated by 12% SDS–PAGE, transferred to nitrocellulose membranes, and probed with rabbit anti-caveolin-1 in Western blot assays as described above. Interaction(s) of caveolin-1 mutants with SCP-2₁₋₃₂ were monitored also with full-length caveolin-1, caveolin-1–156, and caveolin-160–178 that were expressed in InVSc1 yeast.

To verify the specificity of the reactivity of purified SCP-2 with Cav₁₉–₄₀ and Cav₃₄–₅₅-bound Sepharose beads (Figure 5B), the integrated density value (IDV) for each band was determined using a Fluorochrom 8000 Advanced Imager (Alpha Innotech Corp., San Leandro, CA). The average value after background correction was plotted at different concentrations of purified SCP-2 and a constant peptide concentration.

Role of pro-SCP-2 N-Terminal Presequence for Targeting to Peroxisomes: In Vitro FRET. To determine the relative affinity of the C-terminal peroxisomal targeting sequence 1 (PTS-1) present in both SCP-2 and pro-SCP-2, the interaction of these proteins with PEX 5C (peroxisomal receptor for the PTS-1) was examined by FRET. Recombinant PEX 5C was covalently labeled with Cy3 (fluorescence donor), while SCP-2 and pro-SCP-2 were labeled with Cy5 (fluorescence acceptor) by use of a Fluorolink-antibody Cy3 and Cy5-labeling kit (Amersham Biosciences) as indicated by the instructions of the manufacturer. A fixed amount of donor (10 nM PEX 5C) was incubated with increasing amounts of acceptor (Cy5-SCP-2 or Cy5-pro-SCP-2) in PBS at pH 7.4 and 24 °C. Cy3 was excited at 550 nm, and emission was scanned from 560 to 700 nm using a PC1 photon-counting
Table 2: Summary of Phenotypes of Yeast Co-transformed with pD32-Caveolin-1 Mutants and pD22-SCP-2

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>CSM-Leu-Trp-His + 3AT</th>
<th>CSM-Leu-Trp-Ura</th>
<th>CSM-Leu-Trp + 0.2% 5FOA</th>
<th>β-gal CPRG</th>
<th>phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>2+ positive</td>
<td>+</td>
<td>12.5 mM 50 mM 100 mM</td>
<td>−</td>
<td>−</td>
<td>+ 5.890</td>
</tr>
<tr>
<td>1+ positive</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>±</td>
<td>± 0.202</td>
</tr>
<tr>
<td>negative</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>−</td>
<td>− 0.072</td>
</tr>
<tr>
<td>caveolin-1</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>± 1.755</td>
</tr>
<tr>
<td>Cav 1–156</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+ 1.050</td>
</tr>
<tr>
<td>Cav 60–178</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+ 0.068</td>
</tr>
<tr>
<td>Cav A83–123</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+ 1.243</td>
</tr>
<tr>
<td>Cav A60–100</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>± 0.390</td>
</tr>
</tbody>
</table>

*Colonies were replica-plated onto complete synthetic medium lacking Leu, Trp, and histidine (−His) with 12.5, 50, or 100 mM 3-aminotriazole. Colonies were streaked onto complete synthetic medium lacking leucine (−Leu) and tryptophan (−Trp). Colonies were replica-plated onto complete synthetic medium lacking Leu, Trp, and uracil (−Ura). Colonies were replica-plated onto complete synthetic medium lacking Leu and Trp with 0.2% 5-fluoroorotic acid (5FOA). Colonies were replica-plated onto yeast peptone A dextrose plates with nitrocellulose filters. A qualitative β-galactosidase assay was performed using X-gal, resulting in ±, +, or −. A qualitative CPRG assay was performed and reported as β-galactosidase units. Phenotype was determined by combining the results from the differential media to determine a protein–protein interaction.

Co-transformed yeast were monitored for growth on media lacking specific aa and incorporating specific growth inhibitors. Four phenotypes, His* (3AT), β-gal, Ura*, and 5FOA, were used to assess the activation of the chromosomally integrated reporter genes, HIS3, URA3, and LacZ. The control yeast that are supplied with the ProQuest Two-Hybrid System and the transformants grew on plates with CSMLeu-Trp, demonstrating the presence of both co-transformed plasmids, pDest32 and pDest22 vectors (Table 2). Induction of the URA3 gene was shown with growth on CSM-Leu-Trp-Ura plates and the inhibition of growth on CSM-Leu-Trp−0.2% 5FOA. The URA3 promoter, SPO13, has previously been shown to be a weak promoter, yielding a low growth of yeast on plates lacking uracil. The data presented in Table 2 were consistent with this finding. Induction of HIS3 was demonstrated by showing an increased 3AT dose-dependent level of inhibition of growth on CSMLeu-Trp−His−3AT in agreement with the URA3 data (Table 2). The induction of LacZ resulted in positive yeast colonies turning a blue color when assayed on nitrocellulose membranes using X-gal as the substrate (data not shown). All colonies that demonstrated phenotypes interpreted by the four reporter gene readouts as “possible interactors” with weak to little production of β-galactosidase and/or uracil were confirmed and quantitated using the liquid CPRG assay for LacZ expression (Table 2). When the data are taken together, the growth patterns of the co-transformed yeast confirmed the activation of the three reporter genes in the yeast two-hybrid assays and established SCP-2 and caveolin-1 as forming a true protein–protein interaction.

RESULTS

SCP-2 Interacts with Caveolin-1 in a Yeast Two-Hybrid Assay. Although SCP-2 lacks a CBD consensus sequence for interacting with the CSD, the possibility was considered that SCP-2 may still interact through some other interaction with this domain or with another region of caveolin-1. The sequences encoding SCP-2, full-length caveolin-1 (caveolin-1 1–178), and caveolin-1 deletion mutants (Figure 1) were cloned into the ProQuest (Invitrogen) vectors pDEST32 and pDEST22 to produce fusion proteins encoding the GAL4 DNA-binding domain and activating domain, respectively. The resultant plasmids were co-transformed into yeast (MaV203) and initially grown on CSMLeu-Trp−plates with transformation efficiencies of ~2–5 × 10⁶ transformants/μg of plasmid DNA (data not shown). These data are in the range of the standard efficiencies of greater than 1 × 10⁶ transformants/μg of plasmid DNA (49).

Localization of the Binding Site of SCP-2 to the N-Terminal Region of Caveolin-1. The following deletion mutants were utilized to determine the region of caveolin-1 that interacts with SCP-2: (i) Caveolin-1 1–156, a C-terminal deletion mutant of Cav-1 missing most of the C-terminal cytoplasmic domain, (ii) Cav 60–178, an N-terminal deletion mutant of caveolin-1 missing almost all of the N-terminal cytoplasmic domain except for the signature...
Numerous proteins (~48 N-terminal aa 1-68 SCP-2 showed a SCP-2 fusion protein at the same SCP-2-specific peptide antibodies or caveolin-1 antibodies the yeast lysates were electroblotted and probed with either (Figure 2). The GAL4 fusion proteins were observed when cotransformed yeast was confirmed by Western blot analyses. Expression of both fusion proteins in Acti...result strongly suggest that caveolin-1 does not bind SCP-2 through the scaffolding and CPRG assay (Table 2). These results strongly suggest that caveolin-1 does not bind SCP-2 through the scaffolding and the N-terminal cytoplasmic domain complemented with the pD32-caveolin-1, -caveolin-1 1-156, -caveolin-1 Δ83-123, -caveolin-1 Δ60-100, and pD32-SCP-2 demonstrated the correct phenotypes (interaction with SCP-2) on the selection media and β-galactosidase activity equal to or greater than the 1+ positive control (data not shown). Likewise, when caveolin-1 and mutants were cloned into pD32 and co-transformed with pD22-SCP-2, the correct phenotypes (interaction with SCP-2) on the selection media were observed and β-galactosidase activity was equal to or greater than the 1+ positive control (Table 2). However, yeast co-transformed with the fusion construct, pD32Cav 60-178, and pD22-SCP-2 failed to demonstrate the correct phenotypes on the test media for a protein–protein interaction and were negative for β-galactosidase activity in both the X-gal assay (data not shown) and CPRG assay (Table 2). These results strongly suggest that caveolin-1 does not bind SCP-2 through the scaffolding domain, the C-terminal cytoplasmic tail, or the signature domain. Instead, the binding site of caveolin-1 for SCP-2 was localized to the N-terminal cytoplasmic domain comprised of caveolin-1 residues 1-59.

SCP-2 and Caveolin-1 GAL4 DNA-Binding Domain- and Activating Domain-Fusion Proteins Were Present in the Co-transformed Yeast. Expression of both fusion proteins in cotransformed yeast was confirmed by Western blot analyses (Figure 2). The GAL4 fusion proteins were observed when the yeast lysates were electrophobotted and probed with either SCP-2-specific peptide antibodies or caveolin-1 antibodies (Figure 2). In Figure 2A, the co-transformed yeast lysates containing pD32-caveolin-1 full length or mutants and pD22-SCP-2 showed a SCP-2 fusion protein at the same Mm (~25.5 kD, lanes 2-5). Whereas in Figure 2B, the caveolin-1 fusion proteins were seen as a dimer (Mm between 60 and 78 kD). For example, pD32-cav Δ83-123 should run at ×62.8 kD because Gal4 calculates as ~16.8 kD and cav Δ83-123 as ~14.6 kD, making the monomer ~31.4 kD and the dimer ~62.8 kD (lane 2), and pD32-caveolin-1 calculates to ~58.8 kD monomer and ~77.6 kD dimer (lane 5). These data corroborated that the fusion proteins encoded on both plasmids were translated in the yeast.

**Direct Interaction of Caveolin-1 with SCP-2 in Vitro:** Role of the SCP-2 N Terminus. The caveolin-1 scaffolding domain (aa 80-100) represents not only the binding sites for numerous proteins (48, 49) but also the membrane lipid raft binding site (68, 69). By analogy, although the SCP-2 N-terminal aa 1-32, an amphipathic α-helix structure (i.e., hydrophobic and cationic faces), comprises an SCP-2 structural domain for the interaction with model membranes containing anionic phospholipids (63-65), it is not known whether SCP-2-1-32 comprises a protein binding (e.g., caveolin-1) domain. To begin to resolve this issue, the N-terminal SCP-2-1-32 was synthesized, coupled to Sepharose 4B beads, and used in an in vitro peptide binding assay, wherein caveolin-1 binding was detected by Western blot analyses. Synthetic peptides corresponding to caveolin-1 residues 2-31, 19-40, 34-55, 76-101, and 161-178 (Table 1), a peptide corresponding to mature 13 kDa SCP-2 aa 1-32 (SCP-2-1-32), a peptide wherein residue aa20L was mutated to E (SCP-2-1-32E20), and a peptide corresponding to the 20 aa precursor of pro-SCP-2 (pro-SCP-2-1-20) present in 15 kDa pro-SCP-2 (61, 62) were synthesized as described earlier (Table 1) (63-65). To confirm the in vitro yeast two-hybrid assay that identified the caveolin-1 N domain as the interaction site with SCP-2, the in vitro peptide binding assay was repeated using yeast lysates expressing full-length caveolin-1 (pY52DCaveolin-1), a caveolin-1 mutant with the putative binding site present (e.g., pY52DCaveolin-1 1-156), and an N-terminal deletion mutant of caveolin-1 with the putative binding site deleted (e.g., pY52DCav 60-178) (Figure 3B). The lack of reactive bands in lanes 1, 2, 3, and 7 (Figure 3B) showed the lack of nonspecific binding of the

**FIGURE 2:** Expression of SCP-2- and caveolin-1-fusion proteins in co-transformed yeast. Untransformed (lanes 1) and co-transformed MaV203 yeast cell lysates containing pD32Cav1Δ83-123 (lanes 2), pD23Cav1Δ60-100 (lanes 3), pD32Cav1 Δ1-156 (lanes 4), and pD32Cav1 (lanes 5) were separated on 12% SDS–PAGE and transferred onto nitrocellulose membranes. The blots were probed with rabbit anti-SCP-2-1-32 (A) or anti-Cav- Δ32 (B) followed by goat anti-rabbit HRP-conjugated secondary antibodies.

**FIGURE 3:** SCP-2-1-32 binding assays: MDCK cell lysates and yeast expressing caveolin-1 (pY52DCav1), MDCK or InvSc-1 cell lysates were incubated with the immobilized SCP-2-1-32 (Sepharose 4B-SCP-2-1-32), separated on 12% SDS–PAGE, transferred to nitrocellulose membranes, probed with rabbit caveolin-1 antisera, and detected as described in the Materials and Methods. (A) Analysis of MDCK (lane 4) and InvSc-1 (lane 3) lysates reacted with Sepharose 4B-SCP-2-1-32. Beads only with either of the lysates served as a negative control (lanes 1 and 2). Unreacted MDCK lysates was utilized as the positive control (lane 5). (B) Sepharose 4B-SCP-2-1-32 reacted with yeast lysates expressing full-length caveolin-1 (lane 4) and caveolin-1 deletion mutants, Cav1 1-156 (lane 5) and Cav1 60-178 (lane 6). Each lysate was reacted with beads only (lanes 1-3) to show specificity with SCP-2-1-32. Lane 7 shows beads and peptide only. (C) Sepharose 4B-SCP-2-1-32 reacted with yeast lysates expressing full-length caveolin-1 (lane 3) and caveolin-1 deletion mutants, Cav1 1-156 (lane 4) and Cav1 60-178 (lane 5). Beads with no peptide were reacted with lysates from either untransformed yeast (InvSc-1) or yeast expressing Cav1 60-178 (lanes 1 and 2, respectively) to show specificity with SCP-2-1-32. Lane 6 shows beads and peptide only. (D) Sepharose 4B-pro-SCP-2-1-20 reacted with yeast lysates expressing full-length caveolin-1 (lane 4) and caveolin-1 deletion mutants, Cav1 1-156 (lane 5) and Cav1 60-178 (lane 6). Lysates were reacted with beads only (lanes 2 and 7) to show specificity with SCP-2-1-32. Lane 1 shows beads and peptide only. Lane 8 shows the specificity of the antibody for caveolin-1 expressed from full-length caveolin-1.
Caveolin-1 Interaction Domain with SCP-2

Sepharose-4B beads and specificity of the antibody. SCP-2, 1-32-linked beads bound to full-length α-caveolin-1 but not β-caveolin-1 (lane 4 in Figure 3B). In contrast, SCP-2, 1-32-linked beads bound to both α- and β-caveolin-1 1-156, missing the C terminus (lane 5 in Figure 3B). Cav 60-178 failed to bind the SCP-2, 1-32-linked beads (lane 6). When these findings are taken together, they not only confirm that the SCP-2, 1-32 binding site is localized to the N terminus of α-caveolin-1 but also that the interaction with the shorter β-caveolin-1 (missing the N-terminal 32 aa present only in α-caveolin-1) became more prominent upon deletion of the caveolin-1 C terminus. These data suggest that the N-terminal SCP-2 interacted with the N terminus of full-length α-caveolin-1 but interacted with β-caveolin-1 only when the α-caveolin-1 C terminus was missing.

Because SCP-2, 1-32 bound the N terminus of caveolin-1, it was important to determine if this correlated with the ability of this SCP-2 domain to bind anionic phospholipids. SCP-2, 1-32 contains an amphipathic helical region containing a basic face, which directly interacts with anionic phospholipids in model membranes (63, 64). Therefore, the amphipathic helical region of SCP-2, 1-32 was disrupted by replacing Leu20 with Glu20 to produce the mutant peptide SCP-2, 1-32E20. In this study, SCP-2, 1-32E20 was coupled to beads and binding to caveolin-1 was determined with the in vitro peptide binding assay using yeast lysates expressing full-length caveolin-1 and caveolin-1 deletion mutants. SCP-2, 1-32E20 interacted with full-length α-caveolin-1 (lane 3 in Figure 3C) and with caveolin-1 deletion mutants, Caveolin-1 1-156 (lane 4 in Figure 3C), but not with the Cav 60-178 (lane 5 in Figure 3C). Again, Western blotting also showed that SCP-2, 1-32E20 primarily interacted only with the full-length α-caveolin-1 form (lane 4 in Figure 3C), but also interacted with the β-caveolin-1 when the C terminus was deleted (lane 4 in Figure 3C). Note that SCP-2, 1-32E20 does not bind to anionic phospholipids (63, 64) and does not exhibit lipid-transfer activity (70). Thus, the ability of SCP-2, 1-32 to interact with the N-terminal region of caveolin-1 shown herein is independent of its ability to bind to anionic phospholipids (63, 64) and elicit lipid transfer (70).

To determine if the 20 aa presequence present in pro-SCP-2 also interacted with caveolin-1, pro-SCP-2, 1-20 was linked to beads and tested for binding to full-length and mutant caveolin-1. Pro-SCP-2, 1-20-linked beads predominantly bound to full-length α-caveolin-1 (lane 4 in Figure 3D), whereas Pro-SCP-2, 1-20 bound to both α- and β-caveolin-1 when the caveolin-1 C terminus was deleted (lane 5 in Figure 3D) but not to Cav 60-178 (lane 6 in Figure 3D). Lane 8 of Figure 3D shows that the yeast express both isoforms of caveolin-1. Thus, in the mature SCP-2, the caveolin-1 binding site was localized in SCP-2, 1-32, while in the pro-SCP-2 precursor, the 20 aa N-terminal presequence also bound. When these data are taken together, they indicate that the SCP-2-caveolin-1 binding site is localized to the N terminus, as suggested with the yeast two-hybrid data, and the caveolin-1 binding also occurs with the 20 aa presequence present in pro-SCP-2.

To examine the caveolin-1—SCP-2 interaction in greater detail, synthetic peptides corresponding to caveolin-1 residues 2-31, 19-40, 34-55, 76-101, and 161-178 were synthesized and attached to CNBr-activated Sepharose 4B beads. In addition, SCP-2 was purified to test the reactivity to the different caveolin-1 peptides in a direct binding assay. The silver stain (inset) and mass chromatogram show the purity of the SCP-2 protein (Figure 4).

Purified SCP-2 and recombinant yeast lysates expressing SCP-2 were reacted with the panel of caveolin-1 synthetic peptides bound to Sepharose beads (Figure 5). Note in all assays the beads alone (no peptide) incubated with InVSc1 lysates were nonreactive. In Figure 5A, Cav, 2-33-bound beads also failed to react with InVSc1 or pY52D-SCP-2 (lanes 2 and 5, respectively). Similarly, Cav 76-101 and 161-178 failed to bind purified SCP-2 (data not shown) or SCP-2 expressed in yeast (parts C and D of Figure 5). When the caveolin-1 N-terminal peptides, Cav, 1-19 and Cav, 1-34-55, were reacted with purified SCP-2, a strong interaction was noted (lanes 2 and 3 in Figure 5B). However, there was a minor interaction between the beads alone with purified SCP-2 (lane 1 in Figure 5B). This pattern was repeatedly observed with purified SCP-2 varying in concentration from 50 to 200 ng and a constant concentration of bound-peptide or beads alone. To rectify this background reactivity, the IDV of equal areas was established for each concentration of SCP-2 reacted against the N-terminal caveolin-1 peptides. The IDV of the light band corresponding to beads alone and SCP-2 were subtracted from the positive values and plotted (Figure 5E). As shown with both 200 and 50 ng of purified SCP-2, the IDV of SCP-2 and Cav, 1-34-55 was consistently higher than that observed with Cav, 34-55, suggesting that SCP-2 had a higher affinity for Cav, 1-34 than for Cav, 34-55 (Figure 5E). When these data are taken together, they indicate a specific interaction between SCP-2 and Cav, 1-34 and Cav, 34-55, with a stronger binding with Cav, 1-34.

In summary, the results of the in vitro yeast two-hybrid assays indicated that the caveolin-1 cytoplasmic N-terminal 59 aa contained the SCP-2 binding domain. The in vitro binding assays using SCP-2, 1-32 confirmed that the N terminus of SCP-2 binds to an N-terminal region of caveolin-1 and refined the SCP-2 binding site to the first 32

Figure 4: Mass spectrum and SDS-PAGE analysis of purified recombinant SCP-2. SCP-2 was IPTG-induced and purified from the E. coli strain, W3110, and examined by mass spectrometry and SDS-PAGE with silver stain. The matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrum of SCP-2 is shown. The inset is a photograph of a silver-stained gel after SDS-PAGE of molecular-size markers (lane 1) and 10 mg of SCP-2 (lane 2).
were reacted with SCP-2, washed, separated on a 12% SDS-PAGE, transferred to nitrocellulose, and reacted with anti-sera specific to SCP-2. (A) Yeast expressing SCP-2 only (lane 6) or reacted with beads only (lane 4) or beads bound by the N-terminal caveolin-1 binding domain of SCP-2 to caveolin-1 to Cav1 \textsubscript{19}-34 was linked to Sepharose beads and reacted with unbound beads is shown in lane 1. (C and D) Akin to A, yeast expressing SCP-2 were reacted with caveolin-1 peptide-bound Sepharose beads. C shows reactivity with the Cav1 \textsubscript{19}-31 peptide (aa 2–31, lane 5) and D shows reactivity with Cav1 \textsubscript{161}-178 (lane 5) was reacted with Sepharose beads bound with Cav1 \textsubscript{19}-40 (lane 2) or Cav1 \textsubscript{134}-155 (lane 3). InVSc1 and beads only are shown in lane 4, and purified SCP-2 with unbound beads is shown in lane 1. (C and D) Akin to A, yeast expressing SCP-2 were reacted with caveolin-1 peptide-bound Sepharose beads. C shows reactivity with the Cav1 \textsubscript{19}-40 peptide (aa 2–31, lane 5) and D shows reactivity with Cav1 \textsubscript{161}-178 (lane 6). Controls in both panels included InVSc1 (C, lane 4; D, lanes 2 and 5), expressed SCP-2 only (C, lane 1; D, lane 4), and beads only (no peptide) (D, lane 1). (E) Because of the low reactivity with purified SCP-2 and beads only (see B, lane 1), additional studies were performed using different concentrations of SCP-2 and constant concentrations of Sepharose beads only or bound to peptides. These results are graphically shown in E. The $x$ axis shows the average IDV equivalent to IDV/area. The $y$ axis shows the concentration of purified recombinant SCP-2 reacted with Cav1 \textsubscript{19}-40 (E) or Cav1 \textsubscript{134}-155 (D). The values of the average IDV acquired with SCP-2 reacted with beads only were subtracted from the average IDV of SCP-2 reacted with peptide-bound beads and therefore not shown.

Role of the N-Terminal Presequence of pro-SCP-2 in Receptor Interactions In Vitro. As indicated above, the 20 aa presequence of pro-SCP-2 also interacted with caveolin-1, albeit the functional significance of this finding is not known. Western blot analyses detect only the mature SCP-2, suggesting that the pro-SCP-2 interaction is not physiologically significant (reviewed in ref 39). However, convincing evidence has been presented that demonstrates that the pro-SCP-2 is significantly more targeted to peroxisomes, where the 20 aa presequence is proteolytically cleaved (reviewed in ref 39). This suggests that the 20 aa presequence might be more important for the interaction of the pro-SCP-2 with the peroxisomal receptor (PEX5C), in which the peroxisomal targeting sequence (Pex10) is present in the C terminus of pro-SCP-2 as well as SCP-2. To examine the latter possibility, a FRET assay was used to determine binding affinities of PEX5C for pro-SCP-2 versus SCP-2 as described in the Materials and Methods. PEX5C bound pro-SCP-2 with high affinity, $K_D$ of 2.3 nM, over 12-fold stronger than that for SCP-2 (Table 3). Consistent with the close molecular interaction between PEX5C and these proteins, the respective intermolecular distances were both near 70 Å (Table 3). Further, the intermolecular distance between pro-SCP-2 and PEX5C in the complex was slightly larger than between SCP-2 and PEX5C, reflecting the larger size of the 15 kDa pro-SCP-2 as compared to 13 kDa SCP-2 (Table 3). These data indicate that the pro-SCP-2 interacts significantly more strongly with the peroxisomal receptor PEX5C than does SCP-2 ($p < 0.05$).

A representative image of cells incubated with Cy5-pro-SCP-2 and cholera toxin B-AF488 labeled GM1 showed significant colocalization at PM caveolae. When Cy5 and cholera toxin B-AF488 were simultaneously imaged through separate photomultipliers by LSCM, regardless of whether Cy5-SCP-2 (Figure 8A) or Cy5-pro-SCP-2 (Figure 8C) were incorporated into the cells, cholera toxin B-AF488 labeled GM1 primarily at the cell surface. Some punctuate cholera toxin B-AF488 fluorescence appeared below the PM, reflecting the known very rapid endocytic uptake of L cells (71, 72). A representative image of cells incubated with Cy5-SCP-2 and cholera toxin B-AF488 showed that some Cy5-SCP-2 colocalized with cholera toxin B-AF488 labeled GM1 at the PM (Figure 8B). In contrast, there was much less colocalization in cells incubated with Cy5-pro-SCP-2 and cholera toxin B-AF488 (Figure 8D). Thus, the presence of the N-terminal presequence in pro-SCP-2 resulted in less targeting to the PM caveolae/lipid rafts, consistent with the known preferential targeting of pro-SCP-2 to peroxisomes (reviewed in ref 39).

**DISCUSSION**

Although a large variety of proteins that are important in cell signaling and lipid uptake/efflux reside in PM caveolae, the mechanism whereby these proteins are targeted to caveolae is not completely clear. With regard to proteins involved in signaling, to date, all are thought to directly interact with caveolin-1 through specific aa binding sequences. Each signaling protein is predicted to contain a CBD that recognizes the CSD residing in aa 80–101 of caveolin-1 (47). The CSD is not only important for signaling protein recognition, but also model membrane studies indicate that...
A peptide comprised of the caveolin-1 scaffolding domain is sufficient for membrane interaction and membrane domain formation (68). The membrane interaction component of the scaffolding domain is mediated largely by electrostatic interactions between aa segments rich in basic aa, which interact with/recruit acidic phospholipids to form lipid rafts (68). In contrast, because the CBD interaction motifs of signaling proteins contain very few acidic and even fewer basic aa, it is unlikely that these protein–caveolin-1 interactions occur primarily via electrostatic interactions (48).

Instead, the CBD of interacting signaling proteins is comprised of the recognition sequence...

> Table 3: Interaction of SCP-2 and pro-SCP-2 with PEX 5C

<table>
<thead>
<tr>
<th>FRET pair</th>
<th>quenching</th>
</tr>
</thead>
<tbody>
<tr>
<td>donor</td>
<td>acceptor</td>
</tr>
<tr>
<td>Cy-3-PEX5C</td>
<td>Cy-5-SCP-2</td>
</tr>
<tr>
<td>Cy-3-PEX5C</td>
<td>Cy-5-Pro-SCP-2</td>
</tr>
</tbody>
</table>

$^a$ FRET was performed as described in the Materials and Methods to determine the binding affinity ($K_d$) and intermolecular distance ($R$). $^b$ $p < 0.05$ ($n = 3$) versus SCP-2.

In contrast, because the CBD interaction motifs of signaling proteins contain very few acidic and even fewer basic aa, it is unlikely that these protein–caveolin-1 interactions occur primarily via electrostatic interactions (48). Instead, the CBD of interacting signaling proteins is comprised of the recognition sequence $\Phi X \Phi XXXX \Phi$ or $\Phi XXXX \Phi XX \Phi$, where $\Phi$ is an aromatic aa (Trp, Phe, or Tyr) (12, 48, 49). These data suggest that the relatively hydrophobic CBD must interact with a relatively nonpolar region present within the CSD, possibly via the seven hydrophobic residues known to reside therein (68).

In contrast, the signaling and cholesterol homeostatic functions appear codependent (73). Much less is known about specific aa sequences that target proteins involved in lipid uptake/efflux to caveolae. Of the membrane-associated proteins (SRB1, ABCA1, P-gp, and caveolin-1) involved in cholesterol uptake/efflux, only two of the possible interaction pairs have been demonstrated: (i) cross-linking studies show that ABCA1 directly interacts with caveolin-1, through an as yet unresolved CBD and CSD sequences (22), and (ii) caveolin-1 contains the requisite CBD sequence for interacting with the caveolin CSD (48) and homo-oligomerizes, important for caveolae formation and function in signaling.
and lipid transport (11, 34, 48, 68, 74–76). Of the membrane-associated proteins (SRB1, ABCA1, P-gp, and caveolin-1) involved in cholesterol uptake/efflux, only caveolin-1 has been shown to bind cholesterol in vitro (17), cross-link to photoactivatable cholesterol (31, 73, 77), and mediate bidirectional trafficking of cholesterol to and from caveolae (17, 25, 78). Phosphorylation of Ser 80 within the CSD inhibits sterol binding to caveolin-1 and stimulates cholesterol efflux from cultured cells (73). The fact that SCP-2 is a ubiquitous protein found in all mammalian tissues examined suggests that the SCP-2 interaction with the N terminus of caveolin-1 may facilitate cholesterol efflux when the interaction of caveolin-1 with the CSD is disrupted. To date, the specific membrane protein(s) involved in cholesterol insertion into caveolae, translocation across caveolae, and desorption from caveolae remain to be identified.

Given that the scaffolding domain of caveolin-1 recognizes the binding domain of other caveolin-1 molecules, caveolin-1/caveolin-1 oligomerization may be involved in the docking of caveolar vesicles or caveolin-1/lipid/chaperone complexes that direct cholesterol and cholesteryl ester trafficking to/from caveolae (11, 34, 48, 68, 74, 76). Although FRET and immunogold electron microscopy data from our laboratory suggest that SCP-2 is in sufficient proximity to caveolin-1 for direct interaction in several cultured cell lines, examination of the aa sequence indicates that this cholesterol binding/transport protein does not contain the consensus CBD necessary for interaction with the CSD (50). The data presented herein provided several new insights and demonstrated for the first time a potential new caveolin-1 recognition domain, independent of the CSD motif, for the interaction with proteins not containing the classic CBD domain.

Our previous data show that full-length SCP-2 and full-length caveolin-1 interact in an in vivo yeast two-hybrid assay. This reactivity was further shown by FRET and co-immunoprecipitation strategies, strongly suggesting a direct protein–protein interaction between these molecules (50). Therefore, we evaluated the interaction of caveolin-1 mutants with SCP-2 to determine if SCP-2 bound a specific caveolin-1 domain. Reactivity of purified caveolin-1 synthetic peptides and purified SCP-2 in an in vitro binding assay verified a direct protein–protein interaction. However, we recognize that other molecules may be involved in vivo. Data from the current investigation revealed the following:

First, studies with caveolin-1 mutants in the yeast two-hybrid assays demonstrated that the SCP-2 binding domain was present in the caveolin-1 N-terminal region of both α- and β-caveolin-1 isoforms.

Second, deletion of the α-caveolin-1 N-terminal aa 1–59 abolished binding to the SCP-2, bound beads. Conversely, the N-terminal α-caveolin-1 peptide (Cav2–31) bound to Sepharose beads failed to bind purified SCP-2, whereas SCP-2 bound two caveolin-1 peptides, Cav19–40 and Cav34–55, with the more N-terminal peptide showing stronger reactivity. When these results are taken together, this positive reactivity with Cav19–40 and negative reactivity with Cav2–31 indicated that the SCP-2 binding site encompassed caveolin-1 residues 34–50, a new caveolin-1 binding domain. It should be noted however that, because of alternate transcription sites, the caveolin-1 gene encodes for two isoforms: α-caveolin-1 and β-caveolin-1 (79, 80). These isoforms differ in that the β-caveolin-1 is missing the N-terminal 32 aa (Figure 6). On the basis of the fact that the putative SCP-2 binding site for α-caveolin-1 is residues 34–40, which are also present at the N terminus of β-caveolin-1 (boxed area in Figure 6), it is expected that SCP-2 would interact equally well with both proteins.

Third, the C-terminal deletion mutants of α-caveolin-1 1–156 and β-caveolin-1 1–156 interacted with SCP-2 in vitro peptide binding technique but only weakly bound full-length β-caveolin-1. These data indicate that (i) deletion of the β-caveolin-1 C terminus facilitates exposure of the β-caveolin-1 N terminus to interact with SCP-2, (ii) the α-caveolin-1 C terminus is not essential to SCP-2 binding, and (iii) the caveolin-1 C terminus influences the expression of the caveolin-1 N terminus. This could explain earlier results in which the rotavirus protein NSP4 interacts with both termini of caveolin-1 (54). In this study, the N terminus of caveolin-1 was more reactive in the peptide binding assay than the C terminus of caveolin-1, perhaps because the role of NSP4 binding to the C terminus of caveolin-1 is to expose the N terminus of caveolin-1 to NSP4 for binding. Additional data are needed to verify this hypothesis, although these data are consistent with the mutant caveolin-1 SCP-2 binding results.

Fourth, deletion mutants of caveolin-1 missing all or part of the scaffolding domain (aa 80–100) interacted with SCP-2 in the yeast two-hybrid assay (CavA60–100 and CavA83–
Caveolin-1 Interaction Domain with SCP-2

These data were consistent with SCP-2 lacking the aromatic consensus CBD (50). Thus, SCP-2 interaction with caveolin-1 must be mediated through a domain outside of the caveolin-1 CBD. Our laboratory showed earlier that the SCP-2 N-terminal aa 1–32 has an amphipathic α-helix structure and that one face of this helix is enriched with basic residues that interact with anionic phospholipids in membranes (52, 63). Because both the SCP-2 N terminus (63) and the CSD domain (68) are rich in basic aa (positively charged), this may actually result in an electrostatic repulsion between them and explain in part why SCP-2 does not bind to the CSD.

Fifth, the N-terminal aa 1–32 of SCP-2 were sufficient to provide an interaction domain for caveolin-1. The in vitro binding assay showed that the N-terminal peptide SCP-21–32, coupled to Sepharose beads, captured full-length α-caveolin-1 from lysates of MDCK cells or yeast expressing caveolin-1 but not yeast deficient in caveolin-1. SCP-21–32–Sepharose beads did not capture full-length β-caveolin-1 from MDCK cell lysates. Although the current findings demonstrate that N-terminal SCP-21–32 interacts directly with the N-terminal binding site present in α-caveolin-1, it must be noted that the N-terminal SCP-21–32 also represents the interaction domain with anionic phospholipids of model membranes (63, 64). Circular dichroism (63, 64), nuclear magnetic resonance (NMR), and crystallography studies show that SCP-21–32 is comprised of an amphipathic α helix with hydrophobic residues facing inward in a hydrophobic tunnel (38, 81, 82). The cationic residues face outward for the interaction with membranes containing anionic phospholipids (63) or potentially proteins with patches of anionic residues (38, 81, 82). Caveolin-1 contains a putative α-helical domain at residues 30–40 (78). Modeling studies indicate that this region could interact with the α-helical region of N-terminal SCP-2 (Table 1). To disrupt the amphipathic α helix of SCP-21–32, Leu20 (L20) was replaced with Glu20 (E20). This change results in the loss of binding to anionic phospholipids (63, 64) as well as the loss of both phospholipid and cholesterol transport (70). However, as shown herein, SCP-21–32E20 still interacted with full-length α-caveolin-1, suggesting that the interaction of SCP-2 with caveolin-1 is independent of its ability to bind/transfer cholesterol and phospholipid.

To date, very little is known regarding the functional significance of these two isoforms of caveolin-1 (79). Immunofluorescence and immunogold labeling reveal that the α- and β-caveolin-1 have distinct but overlapping distributions at the PM (80). On the basis of the finding that α-caveolin-1 is localized in deep caveolae, while β-caveolin-1 is localized in shallower caveolae, it has been suggested that α-caveolin-1 may have a greater potential to form caveolae (79). The current investigation extends the potential functional significance of these isoforms by demonstrating that only the full-length α-caveolin-1 but not the β-caveolin-1 interacted with SCP-2 and the N-terminal SCP-21–32. To our knowledge, this is the first report identifying a new protein binding site in the α-caveolin-1 isoform at the N-terminal cytoplasmic region distinct from the scaffolding domain for a cellular protein and the second report of a protein binding outside the CBD/CSD (34).

It is of interest to note that the 20 aa presequence present in pro-SCP-2 also interacted with the N-terminal region of caveolin-1. This N-terminal presequence is flexibly disordered in solution (83, 84), suggesting that the presequence may be available for the interaction with caveolin-1. However, this interaction is not physiologically significant because (i) Western blotting detects only the mature 13 kDa SCP-2 and not the 15 kDa pro-SCP-2 in all mammalian tissues examined as well as in all transfected cells overexpressing pro-SCP-2 examined (reviewed in ref 39); (ii) as shown in the present work, pro-SCP-2 bound nearly 12-fold better than SCP-2 to PEXSC, the receptor for the C-terminal peroxisomal targeting sequence present in both pro-SCP-2 and SCP-2. The higher affinity of PEXSC for pro-SCP-2 versus SCP-2 was recently confirmed by isothermal titration calorimetry (83). The enhanced affinity of the pro-SCP-2 for PEXSC is associated with greater aqueous exposure of the C-terminal peroxisomal targeting sequence 1 in pro-SCP-2 as compared to SCP-2 (60); (iii) the data presented herein show that, as compared to SCP-2, incorporation of pro-SCP-2 into cells resulted in less localization to GM1, a marker for caveolae/lipid rafts at the PM. Photoactivatable GM1 cross-links to caveolin-1 at the PM (85); (iv) expressing the cDNA for pro-SCP-2 in transfected cells resulted in several-fold enhanced peroxisomal targeting compared to the expression of the cDNA encoding SCP-2 (reviewed in ref 39); (v) in normal tissues, the highest concentration of SCP-2 is found in peroxisomes (reviewed in refs 39 and 86); (vi) in all normal tissues and transfected cells overexpressing pro-SCP-2, the 20 aa presequence undergoes complete post-translational cleavage at the peroxisome, followed by degradation (reviewed in ref 39); (vii) there is little difference in the localization of immunoreactive SCP-2 at the PM of cells overexpressing SCP-2 or pro-SCP-2 (50, 87). Thus, the interaction of the 20 aa presequence with caveolin-1 is not likely to be of functional significance because the pro-SCP-2 protein is not detectable.

The SCP-2 interaction with the N-terminal aa 34–40 of caveolin-1 is important in cholesterol trafficking: (i) The SCP-2–N-terminal caveolin-1 interaction was highly selective for the α-caveolin-1, an isoform localized in “deep” caveolae (79), possibly representing more mature caveolae containing a fuller complement of proteins involved in reverse cholesterol transport (RCT); (ii) The binding site in α-caveolin-1 may provide a “docking” area for SCP-2 to influence the activity of caveolin-1 in cholesterol transport as both SCP-2 and caveolin-1 bind cholesterol. Furthermore, the N-terminal binding site of α-caveolin-1 may optimally position SCP-2 to act as either a cholesterol donor or a cholesterol acceptor to/from caveolin-1 or other proteins that interact with caveolin-1 within the caveolar membrane. For example, cross-linking studies show that caveolin-1 does not directly interact with SRB1 or HDL but instead cross-links with ABCA1, which in turn cross-links with HDL (22). When this finding is taken together with the data presented herein, it suggests that SCP-2 transports bound ligand (e.g., cholesterol) from intracellular sites, followed by the interaction with caveolin-1 at the PM for cholesterol efflux via ABCA1 bound to HDL or apoA1. Alternately, SCP-2 bound to α-caveolin-1 in PM caveolae may function as a cholesterol acceptor from HDL tethered to ABCA1 or SRB1 localized in caveolae. These possibilities were differentiated by studies with transfected cells overexpressing SCP-2, which support the latter possibility because these cells exhibited enhanced...
cholesterol uptake (44), increased cholesterol transport from the PM to endoplasmic reticulum for esterification (45, 88, 89), and reduced efflux of cholesterol from lipid-storage droplets (33). These studies with cultured cells are further supported by findings with gene-targeted mice. In controlled fed mice, SCP-2 overexpression induced hepatic cholesterol (unesterified and esterified) accumulation and potentiated the effect of a cholesterol-rich diet to further enhance hepatic cholesterol accumulation (90). In contrast, SCP-2/SCP-x gene ablation reduced hepatic cholesterol (especially cholesterol ester) accumulation (46). When these data are taken together, they suggest that the SCP-2 interaction with caveolin-1 may facilitate cholesterol desorption from caveolae for uptake or retention into the cell rather than for efflux.

Recent reports suggest additional functional significance of the SCP-2 interaction with the N terminus of α-caveolin-1 in lipid signaling. Lipid rafts/caveolae are enriched not only in cholesterol but also in lipids involved in intracellular signaling [phosphatidylinositol (PtdIns), phosphatidylinositol-4-phosphate (PtdIns-4-P), phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2), sphingolipids, gangliosides, ceramide, and diacylglycerol] (47, 51, 78, 91–93). SCP-2 binds and enhances transfer not only of cholesterol but also PI and sphingolipids (35, 39, 94, 95). SCP-2 overexpression redistributes PI from intracellular sites to PM caveolae/lipid rafts (4, 51, 96, 97), redistributes select sphingolipid-signaling lipids to caveolae/lipid rafts (97, 98), stimulates insulin-mediated inositol-triphosphate production (94), and enhances conversion of ceramide to galactosyl-ceramide (95). When both signaling lipids were bound and transferred, such as PI, polyphosphoinositides, and sphingolipids, the SCP-2 interaction with caveolin-1 at PM caveolae may regulate signaling within the cell (reviewed in refs 95 and 97).

In summary, the data presented herein using the yeast two-hybrid system, an in vitro binding assay, and FRET demonstrated for the first time that SCP-2, specifically the N-terminal aa 1–32 amphipathic α helix, interacted with caveolin-1 at a site distinct from the C-terminal caveolin-1 scaffolding domain. Instead, SCP-2 bound caveolin-1 through a new domain identified in the α-caveolin-1 N terminus between aa 34–40. Disruption of the SCP-2 N-terminal amphipathic helical region (i.e., SCP-2,1–32E30) abolished binding to anionic phospholipids (63, 64) and lipid-transfer activity (70) but did not inhibit SCP-2 binding to the α-caveolin-1 N terminus. This indicated that ligand binding to SCP-2 and the SCP-2 interaction with caveolin-1 were independent. While the 20 aa presequence present in pro-SCP-2 also interacts with α-caveolin-1, the physiological significance of this interaction is doubtful because (i) pro-SCP-2 is much more weakly targeted to GM1 located in PM caveolae/lipid rafts; (ii) pro-SCP-2 has a 12-fold stronger affinity than SCP-2 for the peroxisomal receptor of the peroxisomal targeting sequence, and (iii) pro-SCP-2 is much more highly targeted than SCP-2 to peroxisomes, where the N-terminal 20 aa are cleaved such that Western blotting detects only the mature SCP-2. Finally, a more prominent interaction between SCP-2 and β-caveolin-1 was observed when the C terminus of caveolin-1 was deleted. Because α-caveolin-1 is localized primarily in deep caveolae, these findings report one of the first structurally and potentially functionally selective interactions of a soluble lipid carrier with a specific caveolin-1 isofrom.

REFERENCES


